PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections

Phase 1

Completed

Conditions: Bacterial Infections

Interventions: Drug: Dalbavancin

First Posted Date: 2008-05-15

Last Posted Date: 2009-10-12

Lead Sponsor: Pfizer

Target Recruit Count: 10

Registration Number: NCT00678106

Locations: 🇺🇸
Pfizer Investigational Site, Cleveland, Ohio, United States

Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy

Phase 3

Terminated

Conditions: Prostatic Neoplasms

Interventions: Drug: Placebo
Drug: Prednisone
Drug: sunitinib

First Posted Date: 2008-05-13

Last Posted Date: 2013-03-08

Lead Sponsor: Pfizer

Target Recruit Count: 873

Registration Number: NCT00676650

Locations: 🇬🇧
Pfizer Investigational Site, Swansea, United Kingdom

Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients

Phase 3

Terminated

Conditions: Alzheimer Disease

Interventions: Drug: bapineuzumab
Drug: placebo

First Posted Date: 2008-05-12

Last Posted Date: 2016-06-10

Lead Sponsor: Pfizer

Target Recruit Count: 1100

Registration Number: NCT00676143

Locations: 🇺🇸
UPENN Clinical and Transitional Research Center, Philadelphia, Pennsylvania, United States
🇺🇸
Texas Neurology, P.A., Dallas, Texas, United States
🇺🇸
Compass Research, LLC, Orlando, Florida, United States

and more 275 locations

Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer

Phase 3

Terminated

Conditions: Carcinoma, Adenosquamous Cell
Carcinoma, Squamous Cell
Carcinoma, Large Cell
Carcinoma, Non-Small-Cell Lung

Interventions: Drug: CP 751,871 (Figitumumab)
Drug: Erlotinib

First Posted Date: 2008-05-07

Last Posted Date: 2013-07-24

Lead Sponsor: Pfizer

Target Recruit Count: 583

Registration Number: NCT00673049

Locations: 🇬🇧
Pfizer Investigational Site, Manchester, United Kingdom

Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus.

Phase 1

Completed

Conditions: Hepatitis, Chronic
Hepatitis C Virus

Interventions: Drug: Small Molecule Agent (PF-868554)

First Posted Date: 2008-05-05

Last Posted Date: 2014-01-14

Lead Sponsor: Pfizer

Target Recruit Count: 20

Registration Number: NCT00671671

Locations: 🇺🇸
Pfizer Investigational Site, Gainesville, Florida, United States

A Multi-Center, Randomized, Double-Blind, Parallel Group Study To Compare The Efficacy And Tolerability Of Valdecoxib And Diclofenac In Patients With A Sprained Ankle

Phase 4

Completed

Conditions: Pain
Sprains and Strains
Sprain

Interventions: Drug: valdecoxib
Drug: diclofenac

First Posted Date: 2008-05-05

Last Posted Date: 2008-05-05

Lead Sponsor: Pfizer

Target Recruit Count: 202

Registration Number: NCT00671320

Locations: 🇵🇪
Pfizer Investigational Site, Lima, Peru

Varenicline Observational Investigation In The Cessation of Smoking

Completed

Conditions: Smoking Cessation

Interventions: Drug: Varenicline

First Posted Date: 2008-04-30

Last Posted Date: 2015-07-23

Lead Sponsor: Pfizer

Target Recruit Count: 567

Registration Number: NCT00669240

Locations: 🇸🇮
Pfizer Investigational Site, Maribor, Slovenia

A Phase 1/2A, Single Dose Study Of PF-04383119 In Japanese Patients With Moderate To Severe Pain From Osteoarthritis Of The Knee

Phase 2

Completed

Conditions: Osteoarthritis, Knee

Interventions: Drug: PF-04383119 (tanezumab)

First Posted Date: 2008-04-30

Last Posted Date: 2021-02-21

Lead Sponsor: Pfizer

Target Recruit Count: 83

Registration Number: NCT00669409

Locations: 🇯🇵
Medical Corporation Yamamoto Kinenkai Yamamoto Kinen Hospital, Yokohama-shi, Kanagawa-ken, Japan
🇯🇵
Nippon Kokan Clinic, Kawasaki, Kanagawa, Japan
🇯🇵
FuruKawabashi Hospital, Minato-ku, Tokyo, Japan

and more 9 locations

Bioequivalence Study Of Verapamil

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: verapamil

First Posted Date: 2008-04-29

Last Posted Date: 2009-07-08

Lead Sponsor: Pfizer

Target Recruit Count: 79

Registration Number: NCT00668967

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

Study Of Sunitinib With FOLFIRI In Colorectal Cancer

Phase 2

Completed

Conditions: Unresectable or Metastatic Colorectal Cancer

Interventions: Drug: FOLFIRI (The combination regimen of Irinotecan, l-Leucovorin and 5-Fluorouracil)
Drug: Sunitinib

First Posted Date: 2008-04-29

Last Posted Date: 2011-10-17

Lead Sponsor: Pfizer

Target Recruit Count: 71

Registration Number: NCT00668863

Locations: 🇯🇵
Pfizer Investigational Site, Minoh/Osaka, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy